Eureka Therapeutics has developed the InvisiMask, an investigational daily human antibody nasal spray designed to neutralize SARS-CoV-2, nvision the InvisiMask nasal spray to be used daily to provide an important line of personal protection against SARS-CoV-2 infection. 

Eureka Therapeutics

San Francisco

Eureka Therapeutics startup from San Francisco, United States is ranked 1254 out of 2449 worldwide and 458 from the 748 startups in United States. See more information and additional rankings on the StartupBlink Global Ecosystem Map